What is Zacks Research's Estimate for Palomar Q2 Earnings?

Key Points

• Zacks Research raised its Q2 2027 EPS estimate for Palomar to $2.41 (from $2.37) and materially lifted its FY2027 view to $10.26 (from $9.66), while slightly trimming Q1 2028 and FY2028 forecasts.
• Palomar recently reported $2.24 EPS for the latest quarter, beating estimates by $0.18, with revenue of $253.36 million—up 62.7% year‑over‑year.
• Sell‑side sentiment is mostly constructive (six Buys, one Hold; average target $165.50), but insiders have been net sellers recently amid high institutional ownership (~90%).

Palomar Holdings, Inc. (NASDAQ:PLMR - Free Report) - Equities research analysts at Zacks Research boosted their Q2 2027 earnings estimates for Palomar in a research note issued to investors on Thursday, April 9th. Zacks Research analyst Team now expects that the company will post earnings of $2.41 per share for the quarter, up from their prior forecast of $2.37. The consensus estimate for Palomar's current full-year earnings is $5.99 per share. Zacks Research also issued estimates for Palomar's Q4 2027 earnings at $2.12 EPS, FY2027 earnings at $10.26 EPS, Q1 2028 earnings at $2.94 EPS and FY2028 earnings at $11.46 EPS.

Palomar (NASDAQ:PLMR - Get Free Report) last issued its quarterly earnings results on Wednesday, February 11th. The company reported $2.24 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.06 by $0.18. Palomar had a net margin of 22.50% and a return on equity of 22.77%. The business had revenue of $253.36 million for the quarter, compared to analyst estimates of $204.58 million. During the same period in the previous year, the business posted $1.52 earnings per share. The business's revenue was up 62.7% compared to the same quarter last year.

PLMR has been the topic of several other reports. Wall Street Zen lowered shares of Palomar from a "buy" rating to a "hold" rating in a research report on Sunday, March 1st. Keefe, Bruyette & Woods upped their target price on shares of Palomar from $183.00 to $186.00 and gave the stock an "outperform" rating in a research report on Tuesday. Weiss Ratings lowered shares of Palomar from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Tuesday. Evercore began coverage on shares of Palomar in a research report on Monday, February 9th. They set an "outperform" rating and a $150.00 target price on the stock. Finally, JPMorgan Chase & Co. upped their target price on shares of Palomar from $155.00 to $160.00 and gave the stock an "overweight" rating in a research report on Monday, February 23rd. Six investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $165.50.

Palomar Trading Up 4.2%

Shares of PLMR opened at $133.72 on Friday. The firm's 50-day moving average is $123.44 and its two-hundred day moving average is $123.32. Palomar has a twelve month low of $107.75 and a twelve month high of $175.85. The firm has a market capitalization of $3.57 billion, a P/E ratio of 18.62 and a beta of 0.54.

Insiders Place Their Bets

In other news, CFO T Christopher Uchida sold 783 shares of the stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $128.04, for a total value of $100,255.32. Following the sale, the chief financial officer directly owned 14,752 shares in the company, valued at $1,888,846.08. This represents a 5.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Angela L. Grant sold 260 shares of the stock in a transaction that occurred on Saturday, January 31st. The shares were sold at an average price of $121.75, for a total transaction of $31,655.00. Following the completion of the sale, the insider owned 7,033 shares in the company, valued at $856,267.75. This represents a 3.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 63,808 shares of company stock valued at $7,814,365. Corporate insiders own 3.70% of the company's stock.

Institutional Trading of Palomar

Large investors have recently modified their holdings of the business. Salomon & Ludwin LLC acquired a new stake in shares of Palomar in the third quarter valued at approximately $25,000. Richardson Financial Services Inc. grew its position in shares of Palomar by 210.0% in the third quarter. Richardson Financial Services Inc. now owns 217 shares of the company's stock valued at $25,000 after purchasing an additional 147 shares during the last quarter. Geneos Wealth Management Inc. purchased a new position in shares of Palomar during the fourth quarter valued at approximately $32,000. Kestra Advisory Services LLC purchased a new position in shares of Palomar during the fourth quarter valued at approximately $33,000. Finally, Rockefeller Capital Management L.P. lifted its stake in shares of Palomar by 81.5% during the fourth quarter. Rockefeller Capital Management L.P. now owns 294 shares of the company's stock valued at $40,000 after buying an additional 132 shares during the period. 90.25% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Palomar

Here are the key news stories impacting Palomar this week:

• Positive Sentiment: Zacks Research raised its FY2027 EPS view materially (to $10.26 from $9.66), and nudged Q2 and Q4 2027 quarter estimates higher — signaling stronger near‑term underwriting and fee revenue expectations. (Zacks coverage noted below) Why Palomar (PLMR) is a Top Growth Stock for the Long-Term
• Positive Sentiment: Several sell‑side firms remain constructive: Keefe, Bruyette & Woods and JPMorgan have raised price targets and maintained outperform/overweight stances this year, supporting investor sentiment. MarketBeat PLMR coverage
• Neutral Sentiment: Industry pieces (Zacks/MSN) continue to classify Palomar as a long‑term growth opportunity in P&C/stop‑loss space — useful context for longer‑horizon investors but not an immediate earnings catalyst. MSN article
• Neutral Sentiment: Institutional ownership is high (~90%), and reported hedge‑fund / RI moves are small — limited immediate impact on liquidity or control. (Market data summarized in recent reports) MarketBeat PLMR holdings
• Negative Sentiment: Zacks trimmed its Q1 2028 EPS forecast (to $2.94 from $3.17) and reduced its FY2028 view modestly (to $11.46 from $11.83), which is a near‑term headwind to forward expectations and could cap multiple expansion.
• Negative Sentiment: Palomar’s President, Jon Christianson, sold 3,000 shares (~$375k) under a pre‑arranged Rule 10b5‑1 plan; while disclosed as pre‑arranged, insider sells can still pressure sentiment. Insider trade filing

About Palomar

Palomar Holdings, Inc NASDAQ: PLMR is a specialty insurance holding company focused on providing medical stop-loss coverage and related administrative services to self-funded employer health plans in the United States. The firm operates through two primary business segments—Medical Stop-Loss and Specialty Program Management—to deliver tailored risk protection and comprehensive program administration.

In its Medical Stop-Loss segment, Palomar underwrites excess and aggregate stop-loss policies designed to shield self-insured employers from catastrophic medical claims that exceed pre-determined retention levels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.